Scarica l'app Stockscreener
1.68
0.59%
-0.01
Dopo l'orario di chiusura:
1.67
-0.01
-0.60%
Precedente Chiudi:
$1.69
Aprire:
$1.66
Volume 24 ore:
64,637
Relative Volume:
0.18
Capitalizzazione di mercato:
$3.09M
Reddito:
$6.59M
Utile/perdita netta:
$-18.12M
Rapporto P/E:
-0.1776
EPS:
-9.4605
Flusso di cassa netto:
$-11.45M
1 W Prestazione:
-12.95%
1M Prestazione:
-49.93%
6M Prestazione:
+4.52%
1 anno Prestazione:
-92.49%
Intervallo 1D:
$1.65
$1.7213
Intervallo di 1 settimana:
$1.65
$1.895
Portata 52W:
$1.50
$29.28
Hcw Biologics Inc Stock (HCWB) Company Profile
Nome
Hcw Biologics Inc
Settore
Industria
Telefono
954-842-2024
Indirizzo
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
1.68 | 3.54M | 6.59M | -18.12M | -11.45M | -9.4605 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hcw Biologics Inc Borsa (HCWB) Ultime notizie
HCW Biologics Announces Special Meeting for Stockholder Vote on Warrant Issuance Linked to July 2026 Private Placement - kalkinemedia.com
HCW Biologics prices $1.5M private placement offering By Investing.com - Investing.com Australia
HCW Biologics Announces Strategic $1.5 Million Financing - TipRanks
HCW Biologics Raises $1.5 Million in Private Placement of Pre-Funded Warrants; Common Warrants Pending Vote - TradingView
HCW Biologics prices $1.5M private placement offering - Investing.com
HCW Biologics Prices $1.5 Million Private Placement With Existing Stockholder - Quiver Quantitative
HCW Biologics Announces Pricing of $1.5 Million Private Placement - GlobeNewswire
HCW Biologics Board Withdraws Performance Equity Plan Proposal After Stockholder Feedback - Minichart
HCW Biologics Updates Special Meeting Proxy Materials - TipRanks
HCW Biologics removes equity-plan proposal, reschedules special meeting - TradingView
HCW Biologics (HCWB) asks holders to lift warrant share cap - Stock Titan
HCW Biologics regains Nasdaq bid price compliance - scanx.trade
HCWB Looks 92.8% Undervalued on GF Value™ Despite Financial Dist - GuruFocus
HCW Biologics signs global HCW11-006 distribution deal - TipRanks
HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent - Yahoo Finance
HCW Biologics signs distribution deal with Akron Biotech By Investing.com - Investing.com Canada
HCWB Stock In Focus As Holders File To Sell 1.24M Shares - timothysykes.com
HCWB Stock Faces Pressure As Shareholders Plan Secondary Sale - StocksToTrade
HCW Biologics signs distribution deal with Akron Biotech - Investing.com
HCW Biologics Enters Exclusive Distribution Agreement with Akron Biotech for HCW11-006 Reagent Commercialization - Quiver Quantitative
A reagent may help make longer-lasting immune cells. HCW Biologics will supply it to Akron. - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Hcw Biologics Stock Price Forecast. Should You Buy HCWB? - StockInvest.us
HCW Biologics (NASDAQ: HCWB) asks investors to vote on more equity than its current share count - Stock Titan
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment - Investing News Network
HCWB Looks 90.0% Undervalued on GF Value™ - GuruFocus
HCW Biologics Strengthens U.S. Patent Estate for Its Lead - GlobeNewswire
HCW Biologics Inc. SEC Filing (Sep 1, 2026) - Stock Titan
HCW Biologics (HCWB) Rises 8.2% to $3.43 as Momentum Builds Toward Key ResistanceBackspread Trade - siam.in
HCW Biologics Inc (HCWB) Valuation: PE, PB & Fair Value Analysis - TradingKey
HCWB Q1 2026 Earnings: EPS Surges to $2.22, Delivering a 182% Surprise Above ExpectationsSpecial Dividend Alert - dars.gov.et
HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion - Investing.com Canada
Human studies showed HCW Biologics’ fusion expanded progenitor T cells and natural killer cells - Stock Titan
HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells - Yahoo Finance
HCW (HCWB) Financial Update: The EPS Result Is Above Expectation in the Latest Reading; Investor Response: The Share Price Adds 2.83% on the DayEarnings Call Transcript - vinanet.vn
HCW (HCWB): Finishes 2.83% Up at $2.18 in the Latest Reading; Range Check: Price Remains Between $2.07 Support and $2.29 ResistanceBPI Bull Confirmed - vinanet.vn
HCW Biologics (NASDAQ: HCWB) registers PIPE, warrant shares - Stock Titan
581,047 Common Stock of HCW Biologics Inc. are subject to a Lock-Up Agreement Ending on 20-AUG-2026. - marketscreener.com
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
HCWB Q1 2026 Earnings: EPS of $2.22 Smashes Consensus by 182.44% Despite No RevenueHigh Estimate Range - vinanet.vn
HCW Biologics (HCWB) Slides 8.4% to $2.68 as Key Support Level Comes into FocusDividend Arbitrage - vinanet.vn
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results - The Manila Times
HCW Biologics requests FDA meeting for HCW11-018b solid tumor candidate - scanx.trade
HCW Biologics Q2 net loss widens to $5.2M despite revenue surge - scanx.trade
Form 8K HCW Biologics Inc For: 14 August By Investing.com - Investing.com Nigeria
HCW Biologics Inc. Q2 2026: Revenue $135.6K, EPS $(11.58) — 10-Q Summary - TradingView
HCW Biologics (HCWB) posts higher 2026 revenue but flags going-concern risk - Stock Titan
HCW Biologics Reports Second Quarter 2026 Financial Results and Updates HCW9302 Alopecia Areata Program, HCW11-018b Development and Financing Activities - Quiver Quantitative
HCW Biologics trial: 3 alopecia patients cut SALT scores 25%+ - Stock Titan
HCWB Q1 2026 Earnings: Surprise EPS of $2.22 vs. Expected Loss, Yet Shares Slip 3.06%Core Business Growth - dars.gov.et
HCW Biologics Inc (HCWB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Hcw Biologics Inc Azioni (HCWB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Hcw Biologics Inc Azioni (HCWB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Flowers Lee | SVP of Business Development |
Jul 29 '26 |
Buy |
2.58 |
7,736 |
19,998 |
8,691 |
| GARRETT SCOTT T | Director |
Jul 29 '26 |
Buy |
2.58 |
7,736 |
19,998 |
41,644 |
| Wong Hing C | Chief Executive Officer |
May 22 '26 |
Buy |
1.41 |
113,879 |
160,000 |
615,790 |
| GARRETT SCOTT T | Director |
May 22 '26 |
Buy |
1.41 |
177,936 |
250,000 |
203,441 |
| Byam Rebecca | Chief Financial Officer |
May 22 '26 |
Buy |
1.41 |
14,235 |
20,000 |
57,245 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):